153 related articles for article (PubMed ID: 27324386)
1. Plasmablastic lymphoma: successful management with CHOP and lenalidomide in resource constraint settings.
Yanamandra U; Sahu KK; Jain N; Prakash G; Saikia U; Malhotra P
Ann Hematol; 2016 Oct; 95(10):1715-7. PubMed ID: 27324386
[No Abstract] [Full Text] [Related]
2. Solitary plasmablastic lymphoma in the esophagus.
Mihara K; Sasaki N; Mamoru O; Kanbe M; Ichinohe T; Suehiro S
Ann Hematol; 2016 Apr; 95(5):845-6. PubMed ID: 26925582
[No Abstract] [Full Text] [Related]
3. Primary Maxillary Sinus Plasmablastic Lymphoma in HIV/AIDS.
Basavaraj A; Kadam M; Kadam DB
J Assoc Physicians India; 2016 May; 64(5):71-72. PubMed ID: 27735156
[TBL] [Abstract][Full Text] [Related]
4. Human immunodeficiency virus-related lymphoma: prognostic factors predictive of survival.
Taillan B; Garnier G; Schneider S; Pesce A; Fuzibet JG; Dujardin P
Cancer; 1993 May; 71(9):2881-2. PubMed ID: 7682156
[No Abstract] [Full Text] [Related]
5. Bortezomib-contained chemotherapy and thalidomide combined with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) play promising roles in plasmablastic lymphoma: a case report and literature review.
Cao C; Liu T; Zhu H; Wang L; Kai S; Xiang B
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):e145-50. PubMed ID: 25225082
[No Abstract] [Full Text] [Related]
6. HIV-related lymphoma treated with maintenance thalidomide.
Larson ML; Enschede SH; Gregory SA
Clin Adv Hematol Oncol; 2005 Mar; 3(3):231-4; discussion 234-5. PubMed ID: 16166993
[No Abstract] [Full Text] [Related]
7. Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma.
Fedele PL; Gregory GP; Gilbertson M; Shortt J; Kumar B; Opat S; Grigoriadis G
Ann Hematol; 2016 Mar; 95(4):667-8. PubMed ID: 26801792
[No Abstract] [Full Text] [Related]
8. Lenalidomide in combination with R-CHOP (R2-CHOP) in patients with high burden follicular lymphoma: phase 2 study.
Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 6):12; 14-5. PubMed ID: 24870876
[No Abstract] [Full Text] [Related]
9. [HIV-negative plasmablastic lymphoma attaining sustained remission with bortezomib-combined dose-adjusted EPOCH therapy].
Kobayashi H; Miyagi N
Rinsho Ketsueki; 2017; 58(5):443-448. PubMed ID: 28592757
[TBL] [Abstract][Full Text] [Related]
10. [Clinical features and outcomes: analysis of 9 cases of HIV-negtive plasmablastic lymphoma].
Gui L; He XH; Liu P; Yang JL; Qin Y; Zhou SY; Yang S; Zhang CG; Shi YK
Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):762-767. PubMed ID: 27719718
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.
Castillo JJ; Guerrero-Garcia T; Baldini F; Tchernonog E; Cartron G; Ninkovic S; Cwynarski K; Dierickx D; Tousseyn T; Lansigan F; Linnik Y; Mogollon R; Navarro JT; Olszewski AJ; Reagan JL; Fedele P; Gilbertson M; Grigoriadis G; Bibas M
Br J Haematol; 2019 Feb; 184(4):679-682. PubMed ID: 29527667
[No Abstract] [Full Text] [Related]
12. Dramatic efficacy of low dose lenalidomide as single agent in a patient with refractory gastric non-human immunodeficiency virus-associated plasmablastic lymphoma.
Carras S; Regny C; Peoc'h M; Gervasoni J; Gressin R; Cahn JY; Molina L
Leuk Lymphoma; 2015; 56(10):2986-8. PubMed ID: 25676034
[No Abstract] [Full Text] [Related]
13. Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma.
Miles SA; McGratten M
J Clin Oncol; 2005 Jan; 23(1):247-8. PubMed ID: 15625386
[No Abstract] [Full Text] [Related]
14. A Case of Plasmablastic Lymphoma Achieving Complete Response and Durable Remission after Lenalidomide-Based Therapy.
Schmit JM; DeLaune J; Norkin M; Grosbach A
Oncol Res Treat; 2017; 40(1-2):46-48. PubMed ID: 28095384
[TBL] [Abstract][Full Text] [Related]
15. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy.
Mounier N; Spina M; Gabarre J; Raphael M; Rizzardini G; Golfier JB; Vaccher E; Carbone A; Coiffier B; Chichino G; Bosly A; Tirelli U; Gisselbrecht C
Blood; 2006 May; 107(10):3832-40. PubMed ID: 16410446
[TBL] [Abstract][Full Text] [Related]
16. Therapy of HIV-associated lymphoma-recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG).
Hentrich M; Hoffmann C; Mosthaf F; Müller M; Siehl J; Wyen C; Hensel M; ;
Ann Hematol; 2014 Jun; 93(6):913-21. PubMed ID: 24807241
[TBL] [Abstract][Full Text] [Related]
17. Refractory plasmablastic lymphoma-a review of treatment options beyond standard therapy.
Pretscher D; Kalisch A; Wilhelm M; Birkmann J
Ann Hematol; 2017 Jun; 96(6):967-970. PubMed ID: 28011983
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
Boué F; Gabarre J; Gisselbrecht C; Reynes J; Cheret A; Bonnet F; Billaud E; Raphael M; Lancar R; Costagliola D
J Clin Oncol; 2006 Sep; 24(25):4123-8. PubMed ID: 16896005
[TBL] [Abstract][Full Text] [Related]
19. Non-Hodgkin's lymphoma associated with human immunodeficiency virus: treatment with LNH 84 regimen in a selected group of patients.
Gisselbrecht C; Oksenjendler E; Tirelli U; Gabarre J; Gastaldi R; Farcet JP; Thyss A; Coiffier B; Raphael M; Lepage E
Leukemia; 1992; 6 Suppl 3():10S-11S. PubMed ID: 1376380
[No Abstract] [Full Text] [Related]
20. [Cutaneous presentation of plasmablastic lymphoma in a patient with HIV Infection].
Zaragoza V; Martínez L; Pérez-Ferriols A; Alegre V
Actas Dermosifiliogr; 2008 Dec; 99(10):820-1. PubMed ID: 19091226
[No Abstract] [Full Text] [Related]
[Next] [New Search]
